Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday.
Mylan said in October that it would pay $465 million to resolve allegations it underpaid U.S. government healthcare programs. The company told Reuters in November it was working to finalize that deal.
However, there is no agreement so far, according to the letter to Senator Charles Grassley from the outgoing head of the Centers for Medicare & Medicaid Services (CMS), Andrew Slavitt. The letter was made public by Grassley.
Filed under: Uncategorized |